ImmunoGen and Jazz enter ADC option agreement
ImmunoGen Inc. granted Jazz Pharmaceuticals PLC options to license exclusive global rights to up to three antibody-drug conjugates in development for blood cancers.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.